Results 51 to 60 of about 30,536 (239)
Cancer Science, 2021 Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curative option for patients suffering ...
Yunxiong Wei +10 more
semanticscholar +1 more source
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Haematologica, 2014 Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents.
Haiyang Yun +13 more
doaj +1 more source
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia [PDF]
, 2011 Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a p53-independent treatment ...
Anjali Advani +15 more
core +2 more sources
Application of Small Epigenetic Modulators in Pediatric Medulloblastoma [PDF]
, 2018 Medulloblastoma is one of the most frequent among pediatric brain tumors, and it has been classified in various subgroups. Some of them already benefit from quite good therapeutic options, whereas others urgently need novel therapeutic approaches ...
Annalisa Romanelli +8 more
core +2 more sources
EMBO JournalThe nucleoside analogue decitabine (or 5-aza-dC) is used to treat several haematological cancers. Upon its triphosphorylation and incorporation into DNA, 5-aza-dC induces covalent DNA methyltransferase 1 DNA–protein crosslinks (DNMT1-DPCs), leading to ...
Christopher J. Carnie +19 more
semanticscholar +1 more source
Journal of International Medical Research, 2022 Objective Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy.
Maoyi Xu +3 more
doaj +1 more source
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML [PDF]
, 2014 <b>Background</b>. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors (DNMTi), 5-azacytidine (AzaC) and 5-aza-2’-deoxycytidine (Decitabine),
Adams, Peter +8 more
core +2 more sources
British Journal of HaematologyThis study compared decitabine exposure when administered IV (DEC‐IV) at a dose of 20 mg/m2 for 5‐days with orally administered decitabine with cedazuridine (DEC‐C), as well as the clinical efficacy and safety of DEC‐C in patients with acute myeloid ...
K. Geissler +18 more
semanticscholar +1 more source
FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes.
Clinical Cancer Research, 2022 On July 7, 2020, the Food and Drug Administration approved Inqovi (Otsuka Pharmaceutical Co.), an oral fixed dose combination tablet comprising 35 mg decitabine, a hypomethylating agent, and 100 mg cedazuridine, a cytidine deaminase inhibitor ...
Nina Kim +12 more
semanticscholar +1 more source
Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]
, 2017 Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana +5 more
core +1 more source